Mr. Hunter Land reports
CANOPY GROWTH ANNOUNCES COMPLETION OF STUDY ON THE LONG-TERM EFFECTS OF CBD
Canopy Growth Corp. and its medical division, Spectrum Therapeutics, have completed and published a new study on the long-term effects of cannabidiol (CBD), specifically focusing on toxicity and lifespan effects of CBD in the preclinical model C. elegans.
The study was commissioned to evaluate the solubility, stability, acute toxicity, thermotolerance and effects on lifespan of CBD in C. elegans as part of Canopy Growth's continuing commitment to provide the data required to support and influence public policy through research. To the best of the company's knowledge, this study represents the first long-term toxicity and lifespan research regarding the effects of chronic exposure to cannabidiol -- one of the cannabinoids found in cannabis.
Acute and long-term exposure studies of CBD at physiologically relevant concentrations were studied in the worm model Caenorhabditis elegans (C. elegans) on the basis that 60 to 80 per cent of their genes are shared with humans, and their comparatively short lifespan of two to three weeks makes such studies feasible. In the C. elegans model, which is recognized as a valid model for this kind of research, CBD did not demonstrate any degree of acute or life-long toxicity or related liabilities at physiological concentrations. Instead, CBD extended mean lifespan up to 18 per cent and increased late-stage life activity by up to 206 per cent compared with the untreated controls within the study.
"Despite widespread use of CBD, no lifelong toxicity studies had been conducted to date to determine the impact -- or potential impact -- of long-term exposure to CBD," shared Hunter Land, senior director of translational and discovery science at Canopy Growth. "These results serve as the only CBD lifelong exposure data in an in vivo model to date, and the absence of long-term toxicity gives us the evidence we need as an industry to continue researching the potential health benefits for the broader application of CBD."
The study was conducted in partnership with NemaLife Inc., and is published in Cannabis and Cannabinoid Research journal and available on-line.
While further research into the lifelong use of CBD should be carried out in mammalian models, the C. elegans model indicates a lack of long-term toxicity at physiologically relevant concentrations. Canopy Growth and its medical division Spectrum Therapeutics continue to advance a range of research initiatives aimed at furthering the understanding of -- and unleashing -- the full potential of cannabis.
About Canopy Growth Corp.
Canopy Growth is a world-leading diversified cannabis and cannabinoid-based consumer product company, driven by a passion to improve lives, end prohibition and strengthen communities by unleashing the full potential of cannabis. Leveraging consumer insights and innovation, the company offers product varieties in high-quality dried flower, oil, softgel capsule, infused beverage, edible and topical formats, as well as vaporizer devices by Canopy Growth and industry-leader Storz & Bickel. The company's global medical brand, Spectrum Therapeutics, sells a range of full-spectrum products using its colour-coded classification system and is a market leader in both Canada and Germany. Through the company's award-winning Tweed and Tokyo Smoke banners, it reaches its adult-use consumers and has built a loyal following by focusing on top quality products and meaningful customer relationships. Canopy Growth has entered into the health and wellness consumer space in key markets including Canada, the United States and Europe through BioSteel sports nutrition, and This Works skin and sleep solutions; and has introduced additional federally permissible CBD products to the United States through its First & Free and Martha Stewart CBD brands. Canopy Growth has an established partnership with Fortune 500 alcohol leader Constellation Brands.
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.